XML 110 R37.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Sale of Future Royalties - Narrative (Details) - USD ($) | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Sep. 30, 2022 | Oct. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jan. 01, 2021
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Repayment of liability for sale of future royalties |  |  | $ 11,726,000 | $ 2,474,000 | $ 0 |
Liability related to sale of future royalties |  |  | 310,807,000 | 304,413,000 |  |
Non-cash interest expense for the sale of future royalties |  |  | 18,083,000 | 21,108,000 | 1,450,000 |
Collaboration revenue |  |  | 17,157,000 | 10,287,000 | 63,175,000 |
GSK |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Collaboration revenue |  |  | 17,200,000 | 10,300,000 | $ 63,200,000 |
JEMPERLI Royalty Monetization Agreement |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Repayment of liability for sale of future royalties |  |  | 8,600,000 |  |  |
Issuance costs related to the sale of future royalties |  | $ 400,000 | $ 37,000 |  |  |
Net of proceeds |  | 249,600,000 |  |  |  |
Effective interest rate |  |  | 8.10% |  |  |
JEMPERLI Royalty Monetization Agreement | Sagard |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Proceeds from sale of future royalties |  | 250,000,000 |  |  |  |
Royalties agreement, maximum annual royalty payout capacity |  | 1,000,000,000 |  |  |  |
Royalties and milestones received |  |  | $ 10,400,000 |  |  |
Liability related to sale of future royalties |  | 250,000,000 |  |  |  |
JEMPERLI Royalty Monetization Agreement | Sagard | By the end of 2026 |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Royalties and milestones, agreement amount to be received |  | $ 312,500,000 |  |  |  |
Proceeds, contingent on annual sales milestones upfront |  | 125.00% |  |  |  |
JEMPERLI Royalty Monetization Agreement | Sagard | During 2027 |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Royalties and milestones, agreement amount to be received |  | $ 337,500,000 |  |  |  |
Proceeds, contingent on annual sales milestones upfront |  | 135.00% |  |  |  |
JEMPERLI Royalty Monetization Agreement | Sagard | At any time after 2027 |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Royalties and milestones, agreement amount to be received |  | $ 412,500,000 |  |  |  |
Proceeds, contingent on annual sales milestones upfront |  | 165.00% |  |  |  |
JEMPERLI Royalty Monetization Agreement | GSK |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Non cash royalty revenue, for sale of future royalties |  |  |  | 2,300,000 |  |
Non-cash interest expense for the sale of future royalties |  |  | 17,100,000 | 20,400,000 |  |
Collaboration revenue |  |  | 13,800,000 | 2,300,000 |  |
Zejula Royalty Monetization Agreement |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Repayment of liability for sale of future royalties |  |  | $ 3,126,000 |  |  |
Net of proceeds | $ 34,800,000 |  |  |  |  |
Effective interest rate |  |  | 2.70% |  |  |
Zejula Royalty Monetization Agreement | GSK |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Non-cash interest expense for the sale of future royalties |  |  | $ 1,000,000 | 700,000 |  |
Payment rate |  |  |  |  |  | 1.00%
Settlement agreement rate |  |  |  |  |  | 0.50%
Effective royalty rate |  |  | 0.50% |  |  |
Collaboration revenue |  |  | $ 3,400,000 | $ 1,400,000 |  |
Zejula Royalty Monetization Agreement | DRI Healthcare Trust |  |  |  |  |  |
Liabilities Related To Sale Of Future Royalties [Line Items] |  |  |  |  |  |
Proceeds from sale of future royalties | 35,000,000 |  |  |  |  |
Royalties and milestones, agreement amount to be received | 10,000,000 |  |  |  |  |
Liability related to sale of future royalties | 35,000,000 |  |  |  |  |
Issuance costs related to the sale of future royalties | $ 200,000 |  |  |  |  |

X
- Definition Advance Future Royalties, Aggregate Payment, Threshold + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesAggregatePaymentThreshold
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Advance Future Royalties, Aggregate Payment, Threshold Percent + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesAggregatePaymentThresholdPercent
Namespace Prefix: | anab_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Advance Future Royalties, Annual Sales Threshold + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesAnnualSalesThreshold
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Advance Future Royalties, Effective Royalty Rate + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesEffectiveRoyaltyRate
Namespace Prefix: | anab_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Advance Future Royalties, Interest Rate, Effective Percentage + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesInterestRateEffectivePercentage
Namespace Prefix: | anab_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Advance Future Royalties, Issuance Costs + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesIssuanceCosts
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Advance Future Royalties, Liability, Noncurrent + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesLiabilityNoncurrent
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Advance Future Royalties, Liability, Noncurrent, Net + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesLiabilityNoncurrentNet
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Advance Future Royalties, Minimum Global Net Sales, Rate + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesMinimumGlobalNetSalesRate
Namespace Prefix: | anab_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Advance Future Royalties, Rate + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesRate
Namespace Prefix: | anab_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Cumulative Repayment Of Advance Future Royalty And Milestones + References No definition available. + Details
Name: | anab_CumulativeRepaymentOfAdvanceFutureRoyaltyAndMilestones
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liabilities Related To Sale Of Future Royalties + References No definition available. + Details
Name: | anab_LiabilitiesRelatedToSaleOfFutureRoyaltiesLineItems
Namespace Prefix: | anab_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense + References No definition available. + Details
Name: | anab_NoncashAdvanceFutureRoyaltiesAndAmortizationOfAdvanceFutureRoyaltiesInterestExpense
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Noncash Advance Future Royalties Revenue + References No definition available. + Details
Name: | anab_NoncashAdvanceFutureRoyaltiesRevenue
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Proceeds From Advance Future Royalties + References No definition available. + Details
Name: | anab_ProceedsFromAdvanceFutureRoyalties
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Repayment Of Advance Future Royalty And Milestones + References No definition available. + Details
Name: | anab_RepaymentOfAdvanceFutureRoyaltyAndMilestones
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_JEMPERLIRoyaltyMonetizationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anab_SagardHealthcareRoyaltyPartnersLPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | anab_AdvanceFutureRoyaltiesPaymentAxis=anab_FirstInstallmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | anab_AdvanceFutureRoyaltiesPaymentAxis=anab_SecondInstallmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | anab_AdvanceFutureRoyaltiesPaymentAxis=anab_ThirdInstallmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_ZejulaRoyaltyMonetizationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anab_DRIHealthcareTrustMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |